How This JAK Inhibitor Works for Psoriasis
In September 2022, the FDA approved the first JAK inhibitor to treat moderate-to-severe plaque psoriasis.
This drugs works differently from other immune-suppressing psoriasis treatments.
Back
It blocks tyrosine kinase 2 (TYK2), an enzyme that activates the immune system in response to otherwise harmless triggers, which then leads to inflammation and the buildup of psoriasis plaques.
By targeting TYK2 activity, this drug interrupts the transmission of proinflammatory signals before they even start, which lessens inflammation in the body and improves psoriasis.
This is the first and only medication across any condition that specifically targets the TYK2 pathway, which is part of the JAK family of enzymes.
Replay
